NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Cigna for its Veristrat test for guiding therapy in patients with non-small cell lung cancer.

The decision gives Biodesix more than 115 million covered lives for the test, which uses MALDI mass spec-based proteomic signatures to identify patients likely to respond to treatment with EGFR inhibitors. Cigna has 13.3 million US members.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Jul
12
Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.